Corvus Pharmaceuticals (CRVS) Operating Leases (2019 - 2026)
Corvus Pharmaceuticals' (CRVS) quarterly Operating Leases came in at $406000.0 in Q1 2026, down 51.32% year-on-year from $834000.0 in Q1 2025, and down 23.97% quarter-over-quarter from $534000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Operating Leases (2019 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $406000.0 for Q1 2026.
- On a quarterly basis, Operating Leases fell 51.32% year-over-year to $406000.0 in Q1 2026; TTM through Mar 2026 was $406000.0, a 51.32% decrease from a year earlier, with the FY2025 full-year figure at $534000.0, down 43.01% from the prior year.
- Operating Leases declined to $406000.0 in Q1 2026 per CRVS's latest filing, from $534000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $2.3 million in Q1 2022 and bottomed at $354000.0 in Q3 2023.
- The 5-year median for Operating Leases is $834000.0 (2025), against an average of $999823.5.
- Across the five-year window, Operating Leases surged 216.8% in 2022 and slumped 79.04% in 2023, its largest moves.
- Year by year, Operating Leases stood at $1.4 million in 2022, then rose by 0.07% to $1.4 million in 2023, then slumped by 31.8% to $937000.0 in 2024, then sank by 43.01% to $534000.0 in 2025, then decreased by 23.97% to $406000.0 in 2026.
- Per Business Quant, the three latest CRVS Operating Leases figures stand at $406000.0 (Q1 2026), $534000.0 (Q4 2025), and $632000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Corvus Pharmaceuticals | 1.23 Bn | 1.23 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 406,000.00 |
| Dec 31, 2025 | 534,000.00 |
| Sep 30, 2025 | 632,000.00 |
| Jun 30, 2025 | 728,000.00 |
| Mar 31, 2025 | 834,000.00 |
| Dec 31, 2024 | 937,000.00 |
| Sep 30, 2024 | 354,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 1.04 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Sep 30, 2023 | 354,000.00 |
| Jun 30, 2023 | 700,000.00 |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 1.69 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 2.30 Mn |
| Dec 31, 2021 | 2.60 Mn |
| Sep 30, 2021 | 2.87 Mn |
| Jun 30, 2021 | 631,000.00 |